PTCT
PTC Therapeutics, Inc.
PTCT's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over PTCT overall, supported by stronger fundamentals and stronger modeled upside.
PTCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Strong |
PTCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PTCT PE Valuation
PTCT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PTCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PTCT has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PTCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.93 | — |
| Q3 2026 | -$1.36 | -116% |
| Q2 2026 | -$0.54 | -108% |
| Q1 2026 | -$2.29 | -135% |
| Q4 2025 | $7.78 | +$12.51 |
| Q3 2025 | $8.56 | +$14.51 |
| Q2 2025 | $6.97 | +$13.29 |
| Q1 2025 | $6.51 | +$14.20 |
| Q4 2024 | -$4.73 | +$3.64 |
PTCT has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over PTCT on earnings quality, reporting a profit while its opponent remains loss making.
PTCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +70% |
| Q2 2026 | $360.5M | +102% |
| Q1 2026 | $272.6M | -77% |
| Q4 2025 | $164.7M | -23% |
| Q3 2025 | $211M | +7.2% |
| Q2 2025 | $178.9M | -4.2% |
| Q1 2025 | $1.2B | +460% |
| Q4 2024 | $213.2M | -31% |
PTCT's revenue is recovering but still below its 2025 peak: $358M last quarter, up 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | +5.6 points |
| Q2 2026 | 41% | +61 points |
| Q1 2026 | 17% | -66 points |
| Q4 2025 | -43% | +33 points |
| Q3 2025 | 1.4% | +29 points |
| Q2 2025 | -20% | +2 points |
| Q1 2025 | 83% | +104 points |
| Q4 2024 | -76% | -78 points |
PTCT has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over PTCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
PTCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28M | +$41.8M |
| Q2 2026 | $126.9M | +$186.6M |
| Q1 2026 | -$60.2M | -107% |
| Q4 2025 | -$36.6M | -$2.9M |
| Q3 2025 | -$69.7M | +$7.8M |
| Q2 2025 | -$59.7M | +$4.4M |
| Q1 2025 | $868.4M | +1320% |
| Q4 2024 | -$33.8M | +$72.1M |
PTCT has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
PTCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.3% | -8.5M shares |
| 1 year | -4.2% | -3.6M shares |
| 3 years | +11% | +8.1M shares |
| 5 years | +18% | +12.9M shares |
| Available history | +42% | +24.6M shares |
PTCT has the edge over UNH on shareholder dilution, with a more favorable share count trend.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PTCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q3 2024 | -15.8x | Net Cash |
| Q2 2024 | -51.7x | Net Cash |
PTCT has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PTCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 24.9 | Neutral |
PTCT's weekly RSI is 44 (neutral) and its Stochastic is 25 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PTCT PE vs Healthcare Sector
| Metric | PTCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PTCT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PTCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.4 | 1.5% above |
| 20 week MA | $68.8 | 7.9% below |
| 50 week MA | $70.9 | 11% below |
| 100 week MA | $62.3 | 1.7% above |
| 200 week MA | $49.1 | 29% above |
PTCT's trend is mixed: it's above three of its five weekly moving averages, and 29% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PTCT on trend strength, trading above more of its moving averages.
PTCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.8 | $65.1 | +33% |
| 2021 | $65.1 | $41.9 | -36% |
| 2022 | $41.9 | $36.5 | -13% |
| 2023 | $36.5 | $27.6 | -24% |
| 2024 | $27.6 | $45.2 | +64% |
| 2025 | $45.2 | $78.6 | +74% |
| 2026 YTD | $78.6 | $63.4 | -19% |
PTCT has finished lower in three of the last six years. It's down 19% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PTCT on returns for 2026, with the stronger performance.